Research Interest

Regenerative medicine, immunotherapy, stem cell biology, gene silencing, and cancer treatment. Novel stem cell-based therapies, immune modulation strategies for autoimmune diseases, and innovative cancer immunotherapies. Translational research in cell-based therapeutics, RNA interference, and clinical applications of novel biotechnologies.

Biography

Dr. Thomas E. Ichim is a veteran of multiple startups, backed by a track record of taking technologies from concept to clinic, to exit, across a diverse set of biotechnology disciplines and a seasoned biotechnology entrepreneur and immunologist with extensive experience in advancing medical technologies from concept to clinical application. He has founded and led multiple biotech start-ups, including Medistem Inc., Regen BioPharma, Batu Biologics, and Venvalo Group. His expertise spans regenerative medicine, immunotherapy, and stem cell research, with a strong focus on translating scientific discoveries into commercialized therapies. Dr. Ichim has authored over 100 peer-reviewed publications, wrote and prosecuted over 150 patents and patent applications, wrote Investigational New Drug Application for first fibroblast based cell therapy for disc degenerative disease which was cleared by FDA. Rang opening bell and NASDAQ.